, Tracking Stock Market Picks
Enter Symbol:
Mylan Laboratories, Inc. (MYL) [hlAlert]

up 3.83 %

Mylan Laboratories, Inc. (MYL) rated Buy with price target $70 by Standpoint Research

Posted on: Wednesday,  Aug 26, 2015  10:25 AM ET by Standpoint Research

Standpoint Research rated Buy Mylan Laboratories, Inc. (NASDAQ: MYL) on 08/26/2015, when the stock price was $49.59. Since
then, Mylan Laboratories, Inc. has gained 3.83% as of 12/03/2015's recent price of $51.49.
If you would have followed this Standpoint Research's recommendation on MYL, you would have gained 3.83% of your investment in 99 days.

Mylan Inc. (Mylan) and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients (API). As of May 5, 2009, the Company held a 71.2% interest in Matrix Laboratories Limited (Matrix). Through Matrix, it manufactures and supplies API for its own products and pipeline, as well as for third parties. Mylan has three segments: the Generics Segment, the Matrix Segment and the Specialty Segment. Mylan markets more than 570 products to consumers in more than 140 countries. Mylan?s products cover an array of therapeutic categories, and offer a range of dosage forms and delivery systems, including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products. On June 2, 2008, the Company acquired Merck KGaA?s Central & Eastern Europe (CEE) generics businesses.

Standpoint Research provides independent equity research that is free from the conflicts of asset management, investment banking, proprietary trading, and fee-for-research arrangements. We provide thorough analysis, diagnostics and forecasts on domestic and international equities and markets backed by alpha-generating variables back-tested on many years of data. Standpoint Research currently advises and sells its research to pension funds, hedge funds and asset management firms. Wall Street analysts have an optimistic bias, while we are more objective. In fact some of the variables in our model that are looked at as positives by Wall Street actually carry negative weight in our model. We have a strict discipline that includes running our proprietary 155-variable valuation and diagnostics model with a personal and subjective overlay that has been proven to add value. The effectiveness is demonstrated through our impressive track record of recommendations.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/26/2015 10:25 AM Buy
49.59 70.00
as of 8/27/2015
1 Week up  3.83 %
1 Month   
3 Months   
1 YTD up  3.83 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy